← Browse by Condition
Medical Condition

solid tumor adult

Total Trials
14
Recruiting Now
14
Trial Phases
Phase 2, Phase 1, Phase 2, Phase 1

ClinicalMetric tracks all active clinical trials for solid tumor adult sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — solid tumor adult Clinical Trials

How many clinical trials are currently recruiting for solid tumor adult?
ClinicalMetric currently tracks 14 actively recruiting clinical trials for solid tumor adult, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 14. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for solid tumor adult?
solid tumor adult research spans Phase 1 (9 trials), Phase 2 (8 trials), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a solid tumor adult clinical trial?
Eligibility criteria for solid tumor adult trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
9
Phase 2
8
Phase 3
1
Top Sponsors
Second Affiliated Hospital of Guangzhou Medical University 2 trials
Samsung Medical Center 1 trial
Accession Therapeutics Limited 1 trial
BioInvent International AB 1 trial
Shenzhen Ionova Life Sciences Co., Ltd. 1 trial

Recruiting Clinical Trials

NCT06383884 Phase 2
Recruiting
Patritumab Deruxtecan in Patients With Solid Tumor Harboring an NRG1 Fusion
Enrollment
30 pts
Location
South Korea
Sponsor
Samsung Medical Center
View Trial →
NCT06977737 Phase 1, Phase 2
Recruiting
A Study of ATTR-01 in Participants With Select Epithelial Solid Tumours
Enrollment
72 pts
Location
Spain, United Kingdo...
Sponsor
Accession Therapeutics Limited
View Trial →
NCT04219254 Phase 1, Phase 2
Recruiting
A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Enrollment
197 pts
Location
United States, Georg...
Sponsor
BioInvent International AB
View Trial →
NCT04443088 Phase 1
Recruiting
An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors
Enrollment
78 pts
Location
United States
Sponsor
Shenzhen Ionova Life Sciences ...
View Trial →
NCT05481502
Recruiting
An Exploratory Study to Evaluate Immune Determinants of the Response to Adoptive Cell Therapy (ACT) in Solid and Hematologic Tumors
Enrollment
160 pts
Location
France
Sponsor
Gustave Roussy, Cancer Campus,...
View Trial →
NCT06478108 Phase 2, Phase 3
Recruiting
Interventional Software for Multi-immunotherapy of Solid Tumors
Enrollment
60 pts
Location
China
Sponsor
Second Affiliated Hospital of ...
View Trial →
NCT05223608
Recruiting
Prospective Cohort With Clinic-biologic Database of Patients Treated by Immunotherapy
Enrollment
651 pts
Location
France
Sponsor
Centre Oscar Lambret
View Trial →
NCT03686124 Phase 1, Phase 2
Recruiting
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
Enrollment
375 pts
Location
United States, Germa...
Sponsor
Immatics US, Inc.
View Trial →
NCT04913285 Phase 1
Recruiting
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
Enrollment
400 pts
Location
United States, Austr...
Sponsor
Pierre Fabre Medicament
View Trial →
NCT05868226 Phase 1, Phase 2
Recruiting
PRE-ISPY Phase I/II Oncology Platform Program
Enrollment
280 pts
Location
United States
Sponsor
QuantumLeap Healthcare Collabo...
View Trial →
NCT05947695
Recruiting
Clinical Nurse Specialist Led Early Palliative Survivorship Care for Patients With Advanced Cancer
Enrollment
100 pts
Location
United States
Sponsor
Good Samaritan Hospital Medica...
View Trial →
NCT06196294 Phase 1
Recruiting
GPC3/Mesothelin-CAR-γδT Cells Against Cancers
Enrollment
30 pts
Location
China
Sponsor
Second Affiliated Hospital of ...
View Trial →
NCT06554795 Phase 1, Phase 2
Recruiting
First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors
Enrollment
360 pts
Location
United States, Austr...
Sponsor
DualityBio Inc.
View Trial →
NCT06598007 Phase 1, Phase 2
Recruiting
A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors
Enrollment
78 pts
Location
United States
Sponsor
Crossignal Therapeutics, Inc.
View Trial →

Related Conditions

cancer (2) solid carcinoma (2) lung cancer (2) liver cancer (2) cancer metastatic (1) solid tumor unspecified adult (1) tumor solid (1) solid tumor childhood (1) hematologic cancer (1) refractory cancer (1) recurrent cancer (1) non small cell lung cancer (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology